Log In
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
Forgot your password?
Log In
Don't have an account? Sign Up Here
Join Us
Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
I agree to TheMaven's
Terms
and
Policy
Sign Up
Already have an account? Login here
JIM CRAMER
INVESTING
PERSONAL FINANCE
RETIREMENT
CRYPTO
MARKETS
HOW-TO
VIDEO
FINANCIAL ADVISOR CENTER
TECHNOLOGY
Search
Trade with Jim Cramer 14 Days Free
Join the Action Alerts PLUS Community today!
SUBSCRIBE NOW
LATEST NEWS
JIM CRAMER
Smartsheet, Prudential, Salesforce.com: 'Mad Money' Lightning Round
By Scott Rutt
Jul 10, 2018 6:34 AM EDT
PRESS RELEASES
Editas Medicine Announces Offering Of Common Stock
By GlobeNewswire
Jan 19, 2021 4:01 PM EST
PRESS RELEASES
Editas Medicine Reports On Recent Progress And Outlook At J.P. Morgan Healthcare Conference
By GlobeNewswire
Jan 11, 2021 6:05 AM EST
PRESS RELEASES
Editas Medicine Announces The FDA Has Cleared Initiation Of The EDIT-301 Clinical Trial
By GlobeNewswire
Jan 11, 2021 6:02 AM EST
PRESS RELEASES
Editas Medicine Announces Transition Of Chief Scientific Officer
By GlobeNewswire
Jan 11, 2021 6:00 AM EST
PRESS RELEASES
Editas Medicine To Present At The 39th Annual J.P. Morgan Healthcare Conference
By GlobeNewswire
Jan 4, 2021 4:05 PM EST
PRESS RELEASES
Editas Medicine Names Meeta Chatterjee, Ph.D., To Board Of Directors
By GlobeNewswire
Dec 17, 2020 4:05 PM EST
PRESS RELEASES
Editas Medicine Announces Submission Of IND Application For EDIT-301 With The FDA
By GlobeNewswire
Dec 9, 2020 4:01 PM EST
PRESS RELEASES
Editas Medicine Announces Preclinical Data And Large-Scale Manufacturing Process For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia
By GlobeNewswire
Dec 5, 2020 10:00 AM EST
PRESS RELEASES
Editas Medicine Reports Inducement Grants To New Chief Medical Officer
By GlobeNewswire
Nov 10, 2020 4:01 PM EST
PRESS RELEASES
Editas Medicine To Present At Barclays Gene Editing & Gene Therapy Summit
By GlobeNewswire
Nov 9, 2020 4:05 PM EST
PRESS RELEASES
Editas Medicine Appoints Lisa A. Michaels, M.D., As Chief Medical Officer
By GlobeNewswire
Nov 9, 2020 9:00 AM EST
PRESS RELEASES
Editas Medicine To Participate In Upcoming Investor Conference
By GlobeNewswire
Oct 1, 2020 8:00 AM EDT
PRESS RELEASES
Editas Medicine Announces U.S. Patent And Trademark Office Grants The Broad Institute Priority Benefit In CRISPR Interference
By GlobeNewswire
Sep 11, 2020 7:00 AM EDT
PRESS RELEASES
Editas Medicine To Participate In Upcoming Investor Conferences
By GlobeNewswire
Sep 4, 2020 8:00 AM EDT
PRESS RELEASES
Editas Medicine Receives Rare Pediatric Disease Designation For EDIT-301 For The Treatment Of Sickle Cell Disease
By GlobeNewswire
Aug 24, 2020 8:30 AM EDT
PRESS RELEASES
Editas Medicine Regains Full Global Rights To Ocular Medicines
By GlobeNewswire
Aug 6, 2020 4:01 PM EDT
PRESS RELEASES
Catalent Enters Into Strategic Partnership With Editas Medicine To Support Gene Editing Medicine Pipeline
By GlobeNewswire
Jul 29, 2020 8:00 AM EDT
PRESS RELEASES
Editas Medicine To Host Conference Call Discussing Second Quarter 2020 Results And Corporate Update
By GlobeNewswire
Jul 23, 2020 4:01 PM EDT
PRESS RELEASES
Editas Medicine And Azzur Group Announce A Multi-year Agreement For EDIT-301 And EDIT-201 Manufacturing
By GlobeNewswire
Jul 7, 2020 9:00 AM EDT
PRESS RELEASES
Editas Medicine And Azzur Group Announce A Multi-year Agreement For EDIT-301 And EDIT-201 Manufacturing
By PR Newswire
Jul 7, 2020 9:00 AM EDT
PRESS RELEASES
Editas Medicine Announces Closing Of Offering Of Common Stock And Full Exercise By Underwriter Of Option To Purchase Additional Shares
By GlobeNewswire
Jun 26, 2020 4:05 PM EDT
PRESS RELEASES
Editas Medicine Announces Pricing Of Offering Of Common Stock
By GlobeNewswire
Jun 23, 2020 9:48 PM EDT
PRESS RELEASES
Editas Medicine Announces Offering Of Common Stock
By GlobeNewswire
Jun 23, 2020 4:21 PM EDT
PRESS RELEASES
Editas Medicine Presents Pre-Clinical Data From A Study Of EDIT-301 With Sickle Patient Cells For The Potential Treatment Of Sickle Cell Disease
By GlobeNewswire
Jun 12, 2020 6:00 AM EDT